{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:29:53Z","timestamp":1790281793233,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"a collaborative research grant from Takeda Pharmaceutical Co., Ltd."},{"name":"internal research grants from Keio University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13075-016-1006-1","type":"journal-article","created":{"date-parts":[[2016,5,14]],"date-time":"2016-05-14T04:05:20Z","timestamp":1463198720000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Identification of definitive serum biomarkers associated with disease activity in primary Sj\u00f6gren\u2019s syndrome"],"prefix":"10.1186","volume":"18","author":[{"given":"Ayumi","family":"Nishikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Kassai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuumi","family":"Gotou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiko","family":"Takiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Yoshimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekata","family":"Yasuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Yamaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimpei","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,14]]},"reference":[{"key":"1006_CR1","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","volume":"74","author":"X Mariette","year":"2015","unstructured":"Mariette X, Seror R, Quartuccio L, et al. Efficacy and safety of belimumab in primary Sj\u00f6gren\u2019s syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis. 2015;74:526\u201331.","journal-title":"Ann Rheum Dis."},{"key":"1006_CR2","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1586\/1744666X.2014.876364","volume":"10","author":"Z Brkic","year":"2014","unstructured":"Brkic Z, Versnel MA. Type I IFN signature in primary Sj\u00f6gren\u2019s syndrome patients. Expert Rev Clin Immunol. 2014;10:457\u201367.","journal-title":"Expert Rev Clin Immunol."},{"key":"1006_CR3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1146\/annurev-pathol-012513-104728","volume":"9","author":"CP Mavragani","year":"2014","unstructured":"Mavragani CP, Moutsopoulos HM. Sj\u00f6gren\u2019s syndrome. Annu Rev Pathol Mech Dis. 2014;9:273\u201385.","journal-title":"Annu Rev Pathol Mech Dis."},{"key":"1006_CR4","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","volume":"160","author":"V Devauchelle-Pensec","year":"2014","unstructured":"Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial. Ann Intern Med. 2014;160:233\u201342.","journal-title":"Ann Intern Med."},{"key":"1006_CR5","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.autrev.2012.08.001","volume":"12","author":"D Guellec","year":"2013","unstructured":"Guellec D, Cornec D, Jousse-Joulin S, et al. Diagnostic value of labial minor salivary gland biopsy for Sj\u00f6gren\u2019s syndrome: a systematic review. Autoimmunity Reviews. 2013;12:416\u201320.","journal-title":"Autoimmunity Reviews."},{"key":"1006_CR6","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1586\/1744666X.2014.900441","volume":"10","author":"D Zhou","year":"2014","unstructured":"Zhou D, McNamara NA. Macrophages: important players in primary Sj\u00f6gren\u2019s syndrome? Expert Rev Clin Immunol. 2014;10:513\u201320.","journal-title":"Expert Rev Clin Immunol."},{"key":"1006_CR7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1089\/omi.2010.0134","volume":"15","author":"SK Al-Tarawneh","year":"2011","unstructured":"Al-Tarawneh SK, Border MB, Dibble CF, et al. Defining salivary biomarkers using mass spectrometry-based proteomics: a systematic review. OMICS. 2011;15:353\u201361.","journal-title":"OMICS."},{"key":"1006_CR8","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/rheumatology\/keu405","volume":"54","author":"O Deutsch","year":"2015","unstructured":"Deutsch O, Krief G, Konttinen YT, et al. Identification of Sj\u00f6gren\u2019s syndrome oral fluid biomarker candidates following high-abundance protein depletion. Rheumatology (Oxford). 2015;54:884\u201390.","journal-title":"Rheumatology (Oxford)"},{"key":"1006_CR9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1601-0825.2008.01465.x","volume":"15","author":"Y Fleissig","year":"2009","unstructured":"Fleissig Y, Deutsch O, Reichenberg E, et al. Different proteomic protein patterns in saliva of Sj\u00f6gren\u2019s syndrome patients. Oral Dis. 2009;15:61\u20138.","journal-title":"Oral Dis."},{"key":"1006_CR10","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1586\/14789450.4.6.757","volume":"4","author":"L Giusti","year":"2007","unstructured":"Giusti L, Baldini C, Bazzichi L, et al. Proteomic diagnosis of Sj\u00f6gren\u2019s syndrome. Expert Rev Proteomics. 2007;4:757\u201367.","journal-title":"Expert Rev Proteomics."},{"key":"1006_CR11","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/pmic.201000206","volume":"11","author":"S Hu","year":"2011","unstructured":"Hu S, Vissink A, Arellano M, et al. Identification of autoantibody biomarkers for primary Sj\u00f6gren\u2019s syndrome using protein microarrays. Proteomics. 2011;11:1499\u2013507.","journal-title":"Proteomics."},{"key":"1006_CR12","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1002\/art.22738","volume":"56","author":"G Peluso","year":"2007","unstructured":"Peluso G, De Santis M, Inzitari R, et al. Proteomic study of salivary peptides and proteins in patients with Sj\u00f6gren\u2019s syndrome before and after pilocarpine treatment. Arthritis Rheum. 2007;56:2216\u201322.","journal-title":"Arthritis Rheum."},{"key":"1006_CR13","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/rheumatology\/kei212","volume":"45","author":"OH Ryu","year":"2006","unstructured":"Ryu OH, Atkinson JC, Hoehn GT, et al. Identification of parotid salivary biomarkers in Sj\u00f6gren\u2019s syndrome by surface-enhanced laser desorption\/ionization time-of-flight mass spectrometry and two-dimensional difference gel electrophoresis. Rheumatology. 2006;45:1077\u201386.","journal-title":"Rheumatology."},{"issue":"6","key":"1006_CR14","doi-asserted-by":"crossref","first-page":"R194","DOI":"10.1186\/ar3523","volume":"13","author":"C Baldini","year":"2011","unstructured":"Baldini C, Giusti L, Ciregia F, et al. Proteomic analysis of saliva: a unique tool to distinguish primary Sj\u00f6gren's syndrome from secondary Sj\u00f6gren\u2019s syndrome and other sicca syndromes. Arthritis Res Ther. 2011;13(6):R194.","journal-title":"Arthritis Res Ther"},{"key":"1006_CR15","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/rheumatology\/kes180","volume":"52","author":"L Quartuccio","year":"2013","unstructured":"Quartuccio L, Salvin S, Fabris M, et al. BLyS upregulation in Sj\u00f6gren\u2019s syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology (Oxford). 2013;52:276\u201381.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"1006_CR16","doi-asserted-by":"crossref","first-page":"e59868","DOI":"10.1371\/journal.pone.0059868","volume":"8","author":"JE Gottenberg","year":"2013","unstructured":"Gottenberg JE, Seror R, Miceli-Richardo C, et al. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease acitivity in primary Sj\u00f6gren\u2019s syndrome. data at enrollment in the prospective ASSESS cohort. PLoS One. 2013;8(5):e59868.","journal-title":"PLoS One"},{"key":"1006_CR17","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1136\/annrheumdis-2012-202552","volume":"73","author":"NI Maria","year":"2014","unstructured":"Maria NI, Brkic Z, Waris M, et al. MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis. 2014;73:1052\u20139.","journal-title":"Ann Rheum Dis."},{"key":"1006_CR18","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/ard.2009.110619","volume":"69","author":"R Seror","year":"2010","unstructured":"Seror R, Ravaud P, Bowman S, et al. EULAR Sj\u00f6gren\u2019s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis. 2010;69:1103\u20139.","journal-title":"Ann Rheum Dis."},{"key":"1006_CR19","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/annrheumdis-2013-203736","volume":"73","author":"RV Moerman","year":"2014","unstructured":"Moerman RV, Arends S, Meiners PM, et al. EULAR Sj\u00f6gren\u2019s Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomized controlled trial. Ann Rheum Dis. 2014;73:472\u20134.","journal-title":"Ann Rheum Dis."},{"key":"1006_CR20","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","volume":"6","author":"C Vitali","year":"2002","unstructured":"Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sj\u00f6gren\u2019s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;6:554\u20138.","journal-title":"Ann Rheum Dis."},{"key":"1006_CR21","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/acr.21591","volume":"64","author":"SC Shiboski","year":"2012","unstructured":"Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology classification criteria for Sj\u00f6gren\u2019s syndrome: a data-driven, expert consensus approach in the Sj\u00f6gren\u2019s International Collaborative Clinical Alliance cohort. Arthritis Care Res. 2012;64:475\u201387.","journal-title":"Arthritis Care Res."},{"key":"1006_CR22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3109\/s10165-012-0812-9","volume":"23","author":"H Tsuboi","year":"2013","unstructured":"Tsuboi H, Hagiwara S, Asashima H, et al. Validation of different sets of criteria for the diagnosis of Sj\u00f6gren\u2019s syndrome in Japanese patients. Mod Rheumatol. 2013;23:219\u201325.","journal-title":"Mod Rheumatol."},{"key":"1006_CR23","first-page":"1","volume":"0","author":"P Brito-Zer\u00f3n","year":"2014","unstructured":"Brito-Zer\u00f3n P, Kostov B, Solans R, et al. Systemic activity and mortality in primary Sj\u00f6gren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients. Ann Rheum Dis. 2014;0:1\u20138. doi: 10.1136\/annrheumdis-2014-206418 .","journal-title":"Ann Rheum Dis."},{"key":"1006_CR24","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1038\/mtna.2014.49","volume":"3","author":"JC Rohloff","year":"2014","unstructured":"Rohloff JC, Gelinas AD, Jarvis TC, et al. Nucleic acid ligands with protein-like side chains: modified aptamers and their use as diagnostic and therapeutic agents. Mol Ther Nucleic Acids. 2014;3:e201.","journal-title":"Mol Ther Nucleic Acids."},{"issue":"12","key":"1006_CR25","doi-asserted-by":"crossref","first-page":"e15004","DOI":"10.1371\/journal.pone.0015004","volume":"5","author":"L Gold","year":"2010","unstructured":"Gold L, Ayers D, Bertino J, et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One. 2010;5(12):e15004.","journal-title":"PLoS One"},{"key":"1006_CR26","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1074\/mcp.M113.032136","volume":"13","author":"J Webber","year":"2014","unstructured":"Webber J, Stone TC, Katilius E, et al. Proteomics analysis of cancer exosomes using a novel modified aptamer-based array (SOMAscanTM) platform. Mol Cell Proteomics. 2014;13:1050\u201364.","journal-title":"Mol Cell Proteomics."},{"issue":"5","key":"1006_CR27","doi-asserted-by":"crossref","first-page":"R170","DOI":"10.1186\/ar3493","volume":"13","author":"K Yoshimoto","year":"2011","unstructured":"Yoshimoto K, Tanaka M, Kojima M, et al. Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sj\u00f6gren\u2019s syndrome. Arthritis Res Ther. 2011;13(5):R170.","journal-title":"Arthritis Res Ther"},{"key":"1006_CR28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/ng1935","volume":"39","author":"SA Tomlins","year":"2007","unstructured":"Tomlins SA, Mehra R, Rhodes DR, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet. 2007;39:41\u201351.","journal-title":"Nat Genet."},{"key":"1006_CR29","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jneuroim.2015.04.002","volume":"282","author":"J Markeljevic","year":"2015","unstructured":"Markeljevic J, Sarac H, Bozina N, et al. Serotonin transporter gene polymorphisms: relation with platelet serotonin level in patients with primary Sjogren\u2019s syndrome. J Neuroimmunol. 2015;282:104\u20139.","journal-title":"J Neuroimmunol."},{"key":"1006_CR30","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.3899\/jrheum.121132","volume":"40","author":"H Sarac","year":"2013","unstructured":"Sarac H, Markeljevic J, Erdeljic V, et al. Signal hyperintensities on brain magnetic resonance imaging in patients with primary Sj\u00f6gren\u2019s syndrome and frequent episodic tension-type headache; relation to platelet serotonin level and disease activity. J Rheumatol. 2013;40:1360\u20136.","journal-title":"J Rheumatol."},{"key":"1006_CR31","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/art.39015","volume":"67","author":"N Delaleu","year":"2015","unstructured":"Delaleu N, Mydel P, Kwee I, et al. High fidelity between saliva proteomics and the salivary glands\u2019 biological state defines biomarker-signatures for primary Sj\u00f6gren\u2019s syndrome. Arthritis Rheumatol. 2015;67:1084\u201395.","journal-title":"Arthritis Rheumatol."},{"key":"1006_CR32","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/j.1365-2362.2010.02303.x","volume":"40","author":"A Campar","year":"2010","unstructured":"Campar A, Isenberg DA. Primary Sj\u00f6gren\u2019s syndrome activity and damage indices comparison. Eur J Clin Invest. 2010;40:636\u201344.","journal-title":"Eur J Clin Invest."},{"key":"1006_CR33","doi-asserted-by":"crossref","unstructured":"Nocturne G, Seror R, Fogel O, et al. CXCL13 and CCL11 serum levels and lymphoma and disease activity in primary Sj\u00f6gren Syndrome. Arthritis Rheumatol. 2015. doi:10. 1002\/art.393915.","DOI":"10.1002\/art.39315"},{"key":"1006_CR34","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1002\/art.23966","volume":"58","author":"A Manzo","year":"2008","unstructured":"Manzo A, Vitolo B, Humby F, et al. Mature antigen-experienced T helper cells synthesize and secrete the B cell chemoattractant CXCL13 in the inflammatory environment of the rheumatoid joint. Arthritis Rheum. 2008;58:3377\u201387.","journal-title":"Arthritis Rheum."},{"key":"1006_CR35","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/35876","volume":"391","author":"MD Gunn","year":"1998","unstructured":"Gunn MD, Ngo VN, Ansel KM, et al. A B-cell-homing chemokine made in lymphoid follicles activates Burkitt\u2019s lymphoma receptor-1. Nature. 1998;391:799\u2013803.","journal-title":"Nature."},{"key":"1006_CR36","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1034\/j.1600-065X.2000.00618.x","volume":"176","author":"JG Cyster","year":"2000","unstructured":"Cyster JG, Ansel KM, Reif K, et al. Follicular stromal cells and lymphocyte homing to follicles. Immunol Rev. 2000;176:181\u201393.","journal-title":"Immunol Rev."},{"key":"1006_CR37","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1189\/jlb.0113036","volume":"94","author":"JM Kramer","year":"2013","unstructured":"Kramer JM, Klimatcheva E, Rothstein TL, et al. CXCL13 is elevated in Sj\u00f6gren\u2019s syndrome in mice and humans and is implicated in disease pathogenesis. J Leukoc Biol. 2013;94:1079\u201389.","journal-title":"J Leukoc Biol."},{"key":"1006_CR38","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1002\/art.21062","volume":"52","author":"F Barone","year":"2005","unstructured":"Barone F, Bombardieri M, Manzo A, et al. Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sj\u00f6gren\u2019s syndrome. Arthritis Rheum. 2005;52:1773\u201384.","journal-title":"Arthritis Rheum."},{"key":"1006_CR39","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.4049\/jimmunol.180.7.5130","volume":"180","author":"F Barone","year":"2008","unstructured":"Barone F, Bombardieri M, Rosado MM, et al. CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sj\u00f6gren\u2019s syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization. J Immunol. 2008;180:5130\u201340.","journal-title":"J Immunol."},{"key":"1006_CR40","first-page":"478","volume":"4","author":"DL Fraustman","year":"2013","unstructured":"Fraustman DL, Davis M. TNF receptor 2 and disease: autoimmunity and regenerative medicine. Front Immunol. 2013;4:478.","journal-title":"Front Immunol."},{"key":"1006_CR41","doi-asserted-by":"crossref","unstructured":"Patel M, Oni L, Midgley A, et al. Increased concentration of plasma TNFR1 and TNFR2 in paediatric lupus nephritis. Lupus. 2016;0:1\u20135. doi: 10.1177\/0961203316631634 .","DOI":"10.1177\/0961203316631634"},{"key":"1006_CR42","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","volume":"49","author":"T Horiuchi","year":"2010","unstructured":"Horiuchi T, Mitoma H, Harashima S, et al. Transmembrane TNF-a: structure, function and interaction with anti-TNF agents. Rheumatology. 2010;49:1215\u201328.","journal-title":"Rheumatology."},{"key":"1006_CR43","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1002\/art.11264","volume":"48","author":"E Svenungsson","year":"2003","unstructured":"Svenungsson E, Gunnarsson I, Fei GZ, et al. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha\/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum. 2003;48:2533\u201340.","journal-title":"Arthritis Rheum."},{"key":"1006_CR44","first-page":"42","volume":"34","author":"GA Ferreira","year":"2016","unstructured":"Ferreira GA, Teixeira A, Calderano DC, et al. Atorvastatin reduced soluble receptors of TNF-alpha in systemic lupus erythematosus. Clin Exp Rheumatol. 2016;34:42\u20138.","journal-title":"Clin Exp Rheumatol."},{"key":"1006_CR45","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/03009740701747137","volume":"37","author":"B Turan","year":"2008","unstructured":"Turan B, Pfister K, Diener PA, et al. Soluble tumour necrosis factor receptors sTNFR1 and sTNFR2 are produced at sites of inflammation and are markers of arthritis activity in Beh\u00e7et\u2019s disease. Scand J Rheumatol. 2008;37:135\u201341.","journal-title":"Scand J Rheumatol."},{"key":"1006_CR46","first-page":"131","volume":"19","author":"H Koski","year":"2001","unstructured":"Koski H, Janin A, Humphreys-Beher MG, et al. Tumor necrosis factor-alpha and receptor for it in labial salivary glands in Sj\u00f6gren\u2019s syndrome. Clin Exp Rheumatol. 2001;19:131\u20137.","journal-title":"Clin Exp Rheumatol."},{"key":"1006_CR47","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.biocel.2010.09.001","volume":"43","author":"M Elishmereni","year":"2011","unstructured":"Elishmereni M, Levi-Schaffer F. CD48: a co-stimulatory receptor of immunity. Int J Biochem Cell Biol. 2011;43:25\u20138.","journal-title":"Int J Biochem Cell Biol."},{"key":"1006_CR48","author":"RA Gangwar","year":"2016","unstructured":"Gangwar RA et al. sCD48 is anti-inflammatory in S. aureus Enterotoxin B induced eosinophilic inflammation. Allergy. 2016. doi: 10.1111\/all.12851 .","journal-title":"Allergy"},{"key":"1006_CR49","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4049\/jimmunol.177.1.77","volume":"177","author":"M Ariel","year":"2006","unstructured":"Ariel M et al. CD48 is an allergen and IL-3-induced activation molecule on eosinophils. J Immunol. 2006;177:77\u201383.","journal-title":"J Immunol."},{"key":"1006_CR50","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1023\/A:1027327912204","volume":"17","author":"GM Smith","year":"1997","unstructured":"Smith GM et al. Detection of a soluble form of the leukocyte surface antigen CD48 in plasma and its elevation in patients with lymphoid leukemias and arthritis. J Clinical Immunol. 1997;17:502\u20139.","journal-title":"J Clinical Immunol."},{"key":"1006_CR51","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1034\/j.1600-065X.2001.1810120.x","volume":"181","author":"KS Boles","year":"2001","unstructured":"Boles KS et al. 2B4 (CD244) and CS1: novel members of the CD2 subset of the immunoglobulin superfamily molecules expressed on natural killer cells and other leukocytes. Immunol Rev. 2001;181:234\u201349.","journal-title":"Immunol Rev."},{"key":"1006_CR52","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1136\/ard.2008.095257","volume":"68","author":"S Candon","year":"2009","unstructured":"Candon S, Gottenberg JE, Bengoufa D, et al. Quantitative assessment of antibodies to ribonucleoproteins in primary Sj\u00f6gren\u2019s syndrome: correlation with B-cell biomarkers and disease activity. Ann Rheum Dis. 2009;68:1208\u201312.","journal-title":"Ann Rheum Dis."},{"key":"1006_CR53","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/ard.62.2.168","volume":"62","author":"X Mariette","year":"2003","unstructured":"Mariette X, Roux S, Zhang J, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis. 2003;62:168\u201371.","journal-title":"Ann Rheum Dis."},{"key":"1006_CR54","doi-asserted-by":"crossref","unstructured":"Zhang J, Roschke V, Baker KP, et al. Cutting edge: a role for B lymphocytestimulator in systemic lupus erythematosus. J Immunol. 2001;166:6\u201310.","DOI":"10.4049\/jimmunol.166.1.6"},{"key":"1006_CR55","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S","volume":"44","author":"GS Cheema","year":"2001","unstructured":"Cheema GS, Roschke V, Hilbert DM, et al. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 2001;44:1313\u20139.","journal-title":"Arthritis Rheum."},{"key":"1006_CR56","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cellimm.2014.05.006","volume":"290","author":"S Dai","year":"2014","unstructured":"Dai S, Jia R, Zhang X, et al. The PD-1\/PD-Ls pathway and autoimmune diseases. Cell Immunol. 2014;290:72\u20139.","journal-title":"Cell Immunol."},{"key":"1006_CR57","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.molimm.2011.06.436","volume":"48","author":"N Messal","year":"2011","unstructured":"Messal N, Serriari NE, Pastor S, et al. PD-L2 is expressed on activated human T cells and regulates their function. Mol Immunol. 2011;48:2214\u20139.","journal-title":"Mol Immunol."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-016-1006-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T17:26:21Z","timestamp":1567877181000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-016-1006-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,14]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1006"],"URL":"https:\/\/doi.org\/10.1186\/s13075-016-1006-1","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,14]]},"article-number":"106"}}